One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Search from 250 M+ research papersSearch from 250 M+ research papers
Open Accesshttps://doi.org/10.1002/hon.3163_48
Copy DOI Journal: Hematological Oncology |  Publication Date: Jun 1, 2023 |
 Citations: 3 |
Affiliation: Allogene Therapeutics (United States), Banner Health, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Sarah Cannon, St David's Medical Center, UCLA Health, University of Miami, City Of Hope National Medical Center, Ronald Reagan UCLA Medical Center, Moffitt Cancer Center, Stanford University, Medical College of Wisconsin, Vanderbilt University Medical Center, Norton Healthcare, Mayo Clinic, Colorado Blood Cancer InstituteDURABLES RESPONSES WITH ANTI‐CD19 ALLOGENEIC CAR T ALLO‐501/501A IN PHASE 1 TRIALS OF RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA (<i>R</i>/<i>R</i> LBCL)
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
